4.3.1 Sintesi e raccomandazioni - Biblioteca Medica

ate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS
Study Group. Urology. 1999 Oct; 54(4): 662-9.
13. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic
hyperplasia: a systematic review of randomised trials. BMC Urol. 2002 Dec 12; 2(1):
14.
14. Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK.:
Measuring disease-specific health status in men with benign prostatic hyperplasia.
Measurement Committee of The American Urological Association. Med Care. 1995
Apr;33(4 Suppl):AS145-55.
15. Epstein RS, Deverka PA, Chute CG, Panser L, Oesterling JE, Lieber MM, Schwartz S,
Patrick D.: Validation of a new quality of life questionnaire for benign prostatic
hyperplasia. J Clin Epidemiol. 1992 Dec;45(12):1431-45.
16. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA,
Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J. Effect of finasteride
on bother and other health-related quality of life aspects associated with benign prostatic
hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
Urology. 1999 Oct; 54(4): 670-8.
17. Abrams P, Schafer W, Tammela TL, Barrett DM, Hedlund H, Rollema HJ, Matos-
Ferreira A, Nordling J, Bruskewitz R, Andersen JT, Hald T, Miller P, Kirby R, Mustonen
S, Cannon A, Jacobsen CA, Gormley GJ, Malice MP, Bach MA. Improvement of
pressure flow parameters with finasteride is greater in men with large prostates. Finasteride
Urodynamics Study Group. J Urol. 1999 May; 161(5): 1513-7.
18. Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R, Kandzari
S, Herlihy R, Kornitzer G, Brown BT, Holtgrewe HL, Taylor A, Wang D, Waldstreicher
J. Urinary retention in patients with BPH treated with finasteride or placebo over 4
years. Characterization of patients and ultimate outcomes.The PLESS Study Group.
Eur Urol. 2000 May; 37(5): 528-36.
19. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly
reduces acute urinary retention and need for surgery in patients with symptomatic
benign prostatic hyperplasia. Urology. 1997 Jun;49(6):839-45.
20. Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F, Meehan A,
Stoner E, Waldstreicher J. Prostate volume and serum prostate-specific antigen as
predictors of acute urinary retention. Combined experience from three large
multinational placebo-controlled trials. Eur Urol. 2000 Nov; 38(5): 563-8.
21. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R,
Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J. Serum prostate-specific
antigen concentration is a powerful predictor of acute urinary retention and need for
surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.Urology.
1999 Mar; 53(3): 473-80.
22. Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, Lagerkvist M, Gormley G,
Bach M, Waldstreicher J. Biologic variability of prostate-specific antigen and its usefulness
as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.
Urology. 1998 Apr;51(4A Suppl):58-63
167